The US Federal Trade Commission (FTC) is concerned that major pharma companies are once again paying to defer generic drug launches

Author:  

Publisher: Adis International

ISSN: 1173-5503

Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.503, 2006-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract